Street Calls of the Week
Ionis Pharmaceuticals (NASDAQ:IONS) Executive Vice President, Chief Business Officer Joseph Baroldi, sold 250 shares of common stock at $62.0 on September 5, 2025, for a total of $15,500. The sale was executed under a Rule 10b5-1 trading plan. The transaction comes as the $10.2 billion biotech company’s stock trades near its 52-week high of $64.71, having surged over 90% in the past six months. According to InvestingPro analysis, the stock appears overvalued at current levels, with 12 additional real-time insights available for subscribers.
On the same day, Baroldi also exercised options to acquire 250 shares of Ionis Pharmaceuticals’ common stock at $31.8, for a total value of $7950. The stock currently trades at $64.4, representing a significant premium to the option exercise price.
In other recent news, Ionis Pharmaceuticals announced that its experimental drug ION582 received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of Angelman syndrome. This designation aims to expedite the review process for treatments that show substantial improvement over existing therapies. Additionally, Ionis reported positive results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, demonstrating significant benefits in triglyceride lowering and reducing the risk of acute pancreatitis. Following these developments, H.C. Wainwright raised its price target for Ionis to $95, citing strong triglyceride reductions in pivotal studies. RBC Capital also increased its price target to $80, maintaining an Outperform rating, due to promising data for Ionis’ acute pancreatitis treatment. Furthermore, BMO Capital upgraded Ionis from Market Perform to Outperform, highlighting the potential of Olezarsen as a blockbuster drug. These recent advancements underscore the company’s ongoing efforts in developing treatments for various conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.